Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.80 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 6/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | EGFR | P00533 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.61 |
| ▸ | GMNN | O75496 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4485279 | 1.00 | MAOB (0.80) | MAOBMCL1LMNAGAAEGFR | |
| SCHEMBL4487075 | 0.91 | MAOB (0.83) | MAOBMCL1LMNAGAAEGFR | |
| SCHEMBL4487080 | 0.91 | MAOB (0.83) | MAOBMCL1LMNAGAAEGFR | |
| Ls-104 SCHEMBL3956495 | 0.89 | MAOB (1.00) | MAOBMCL1LMNAGAAEGFR | |
| Ls-104 SCHEMBL3956490 | 0.89 | MAOB (1.00) | MAOBMCL1LMNAGAAEGFR | |
| SCHEMBL3437114 | 0.88 | MAOB (0.68) | MAOBMCL1LMNAGAAEGFR | |
| SCHEMBL3436934 | 0.87 | LMNA (0.70) | MAOBMCL1LMNAGAAEGFR | |
| SCHEMBL4485269 | 0.87 | MCL1 (1.00) | MAOBMCL1LMNAGAAEGFR | |
| SCHEMBL4485275 | 0.87 | MCL1 (1.00) | MAOBMCL1LMNAGAAEGFR | |
| SCHEMBL20397566 | 0.87 | MCL1 (1.00) | MAOBMCL1LMNAGAAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272457-B9 | COMPOUNDS FOR MODULATING CELL PROLIFERATION | HSC RES DEV LP (CA) | 2006-12-20 | — | — | EP | claimed |
| EP-1272457-B1 | COMPOUNDS FOR MODULATING CELL PROLIFERATION | HSC RES DEV LP (CA) | 2006-08-23 | — | — | EP | claimed |
| US-6800659-B2 | NOVEL STYRYLACRYLONITRILE COMPOUNDS WHICH ARE USEFUL IN TREATING A VARIETY OF CELL PROLIFERATIVE DISORDERS SUCH AS CANCER ARE DISCLOSED. A METHOD OF MODULATING CELL PROLIFERATION COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2004-10-05 | — | — | US | claimed |
| US-7598419-B2 | Compounds for modulating cell proliferation | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2009-10-06 | — | — | US | disclosed |
| US-7598419-B2 | Compounds for modulating cell proliferation | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2009-10-06 | — | — | US | disclosed |
| US-7598419-B2 | Compounds for modulating cell proliferation | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2009-10-06 | — | — | US | disclosed |
| US-20070243612-A1 | Novel Compounds for Modulating Cell Proliferation | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2007-10-18 | — | — | US | disclosed |
| US-20070243612-A1 | Novel Compounds for Modulating Cell Proliferation | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2007-10-18 | — | — | US | disclosed |
| US-20070243612-A1 | Novel Compounds for Modulating Cell Proliferation | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2007-10-18 | — | — | US | disclosed |
| EP-1727822-A4 | NOVEL COMPOUNDS FOR MODULATING CELL PROLIFERATION | HSC RES DEV LP (CA) | 2007-05-09 | — | — | EP | disclosed |
| EP-1752446-A2 | Compounds for modulating cell proliferation | HSC Research and Development Limited Partnership (CA) | 2007-02-14 | — | — | EP | disclosed |
| US-20060241084-A1 | Inhibition of vascular endothelial growth factor | THE HOSPITAL FOR SICK CHILDREN (CA) | 2006-10-26 | — | — | US | disclosed |
| EP-1272457-B1 | COMPOUNDS FOR MODULATING CELL PROLIFERATION | HSC RES DEV LP (CA) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005092904-A1 | NOVEL COMPOUNDS FOR MODULATING CELL PROLIFERATION | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2005-10-06 | — | — | WO | disclosed |
| EP-1551381-A2 | STYRYLACRYLONITRILE COMPOUNDS FOR INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR | The Hospital for Sick Children (CA) | 2005-07-13 | — | — | EP | disclosed |
| US-20050014690-A1 | Styryl acrylonitrile compounds and their use to promote myelopoiesis | THE HOSPITAL FOR SICK CHILDREN (CA) | 2005-01-20 | — | — | US | disclosed |
| US-6800659-B2 | NOVEL STYRYLACRYLONITRILE COMPOUNDS WHICH ARE USEFUL IN TREATING A VARIETY OF CELL PROLIFERATIVE DISORDERS SUCH AS CANCER ARE DISCLOSED. A METHOD OF MODULATING CELL PROLIFERATION COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2004-10-05 | — | — | US | disclosed |
| EP-1453500-A1 | STYRYL ACRYLONITRILE COMPOUNDS AND THEIR USE TO PROMOTE MYELOPOIESIS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2004-09-08 | — | — | EP | disclosed |
| WO-2004032911-A2 | STYRYLACRYLONITRILE COMPOUNDS FOR INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR | THE HOSPITAL FOR SICK CHILDREN (CA) | 2004-04-22 | — | — | WO | disclosed |
| WO-2003030895-A1 | STYRYL ACRYLONITRILE COMPOUNDS AND THEIR USE TO PROMOTE MYELOPOIESIS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241084-A1 | Inhibition of vascular endothelial growth factor | VEGFA, FLT4, FLT1 | MAOB 495/4885MCL1 1303/4885LMNA 4824/4885 |
| US-20070243612-A1 | Novel Compounds for Modulating Cell Proliferation | MKI67, CCNA1, PCNA | MAOB 3511/4885MCL1 7/4885LMNA 2293/4885 |
| US-20050014690-A1 | Styryl acrylonitrile compounds and their use to promote myelopoiesis | MCL1, MYD88, MYADM | MAOB 3016/4885MCL1 1/4885LMNA 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.